Vivesto AB
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OASMY research report →
Price Chart
About the company
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers.
- CEO
- Erik Kinnman
- IPO
- 2015
- Employees
- 4
- HQ
- Solna, MD, SE
Get TickerSpark's AI analysis on OASMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.61K
- P/E
- -11.12
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 0.62
- EV/EBITDA
- -1.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21.64%
- ROIC
- -19.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,685,401+0.0%
- Op Income
- $-34,377,000
- Net Income
- $-32,036,734+19.4%
- EPS
- $-0.48+0.0%
- OCF Growth
- +32.4%
- FCF Growth
- +7.3%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.75
- RSI (14)
- 1
- Avg Volume
- 17
No earnings-call transcripts are available for OASMY yet.
- Free Float
- 50.4%
- Shares Outstanding
- 68.69M
- Float Shares
- 34.60M
of shares held by institutions
6 13F filers
Our OASMY coverage
Recent articles, reports, and earnings notes.
No research on OASMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OASMY report →Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)
defenseworld.net · Apr 1
Vivesto AB (OASMY) Discusses Pipeline Advancements in Paccal Vet and Cantrixil and Strategic Capital Raise Transcript
seekingalpha.com · Nov 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.